Literature DB >> 27222000

Fungal infections in children in the early postoperative period after cardiac surgery for congenital heart disease: a single-centre experience.

Radoslaw Jaworski1, Ireneusz Haponiuk2, Ninela Irga-Jaworska3, Maciej Chojnicki4, Mariusz Steffens4, Konrad Paczkowski4, Jacek Zielinski5.   

Abstract

OBJECTIVES: Postoperative infections are still an important problem in cardiac surgery, especially in the paediatric population, and may influence the final outcome of congenital heart disease treatment. Postoperative infections with fungi are uncommon. The aetiology is poorly understood, and the proper diagnosis and treatment is unclear. In this single-centre study, the frequency of invasive fungal disease in children who underwent surgical management of congenital heart diseases was determined along with the risk factors for infection, treatment options and outcomes.
METHODS: All consecutive paediatric patients (<18 years of age) who underwent cardiac surgery for congenital heart disease between September 2008 and December 2015 in a paediatric cardiac centre in Poland were identified. Those who developed invasive fungal disease in the early postoperative period (30 days) were identified.
RESULTS: Of the 1540 cardiosurgical procedures for congenital heart disease, 6 were complicated by fungal infection (0.39%). One patient had a high probability of fungal infection, but the diagnosis was unproved. Nevertheless, the patient was successfully treated with antifungal treatment. Five had proven invasive fungal disease. Of these, 3 were diagnosed with candidaemia. All had undergone cardiopulmonary bypass. Of the remaining 2 patients, 1 was a preterm newborn with complete atrioventricular septal defect who developed rib fungal invasion. The remaining patient had pulmonary atresia with ventricular septal defect and developed Fournier's gangrene after surgery. None of the patients died due to infection in the early postoperative period. However, the child with rib fungal invasion died 39 days after surgery as a result of multiorgan failure.
CONCLUSIONS: Fungal infections in paediatric patients after cardiac surgery may markedly influence morbidity and mortality. Fungal infection prophylaxis in this specific group of children may reduce morbidity, whereas early empirical treatment followed by a targeted approach may improve outcomes. The 'hit fast, hit hard' treatment strategy may be the best rescue option for children who develop invasive fungal disease after cardiac surgery.
© The Author 2016. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Candida albicans; Candidemia; Fournier gangrene; Invasive fungal disease; Pediatric cardiac surgery

Mesh:

Year:  2016        PMID: 27222000     DOI: 10.1093/icvts/ivw156

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  4 in total

1.  Fournier Gangrene Caused by Candida albicans in an Infant After Cardiac Surgery.

Authors:  Radoslaw Jaworski; Ninela Irga-Jaworska; Łukasz Naumiuk; Maciej Chojnicki; Ireneusz Haponiuk
Journal:  Mycopathologia       Date:  2016-11-02       Impact factor: 2.574

2.  Effect of the Kanghuier Transparent Hydrocolloid Dressing in Preventing Central Venous Catheter Infection and Phlebitis after Cardiac Surgery.

Authors:  Xiaoling Han; Jiayi Li; Ping Zeng; Chunfeng Luo; Dongmei Zhou
Journal:  Comput Math Methods Med       Date:  2022-04-01       Impact factor: 2.238

3.  Mycobacterium chimaera - a new threat for cardiac surgical patients?

Authors:  Radosław Jaworski; Łukasz Naumiuk; Konrad Paczkowski; Danuta Formella; Renata Pek; Jacek Zieliński; Ireneusz Haponiuk
Journal:  Kardiochir Torakochirurgia Pol       Date:  2017-03-31

Review 4.  Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children.

Authors:  Jill King; Zoi-Dorothea Pana; Thomas Lehrnbecher; William J Steinbach; Adilia Warris
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.